{"api":"v1","generated_at":"2026-10-02T06:28:40.100Z","licence":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/","attribution":"TOLL, with a link to the page cited"},"page":"https://tollindex.com/e/api-magentlab-com-api-calc-epiphany-d09f3c","pinned_page":"https://tollindex.com/e/api-magentlab-com-api-calc-epiphany-d09f3c/at/2026-10-02T05-34Z","pinned":false,"method":"https://tollindex.com/ledger/method","snapshot_at":"2026-10-02T05:34:29.993Z","snapshot_stamp":"2026-10-02T05-34Z","endpoint":{"slug":"api-magentlab-com-api-calc-epiphany-d09f3c","canonical_url":"https://api.magentlab.com/api/calc/epiphany","resource":"https://api.magentlab.com/api/calc/epiphany","http_method":"POST","type":"http","x402_version":2,"registries":["cdp"],"primary_registry":"cdp","curated_by_coinbase":false,"description":"Carmona-Bayonas 2017 EPIPHANY CHAID tree for cancer-associated PE. Hestia-like CDR any vs none, then ECOG-PS, SaO2, PE symptoms, tumour response, and primary resection as in Figure 2. Returns low, intermediate, or high with 15-day complication rates 1.6/9.4/30.6% and mortality 0.3/6.1/17.1%. Caller assigns the six covariates. Not a diagnosis or anticoagulation order. magent does not examine the patient.","service_name":"magent","declared_category":null,"declared_tags":["epiphany","pe","cancer","vte","calculator"],"route_template":null,"registry_updated":"2026-09-28T14:26:52.747Z"},"derived":{"note":"fields no registry supplies; TOLL derives them and marks them derived on the page","title":"calc epiphany","category":"other","first_observed_by_toll":"2026-09-28T13:51:25.436Z","last_observed_by_toll":"2026-10-02T05:34:29.993Z","observation_began":"2026-09-10"},"presence":{"listed_now":true,"first_absent_at":null,"delisting_confirmed_at":null,"events":[{"registry":"cdp","at":"2026-09-28T13:51:25.437Z","event":"listed"}]},"accepts":[{"registry":"cdp","ordinal":0,"network":"eip155:8453","asset":"0x833589fcd6edb6e08f4c7c32d4f71b54bda02913","asset_name":"USD Coin","symbol":"USDC","decimals":6,"amount_display":"0.005 USDC","amount_units":0.005,"decimals_known":true,"pay_to":"0x836Be278f1739fB4308091cD1852F7971Bc19Ee2","scheme":"exact"}],"counters":{"observed_at":"2026-10-02T05:34:29.993Z","calls_30d":1,"unique_payers_30d":1,"last_called_at":"2026-09-28T14:26:52.613Z"},"validation":{"latest":{"observed_at":"2026-10-01T09:29:06.018Z","state":"pass","failed_checks":[],"endpoint_http_status":402,"run_id":"daily-2026-10-01"},"uptime":[{"days":7,"observed":4,"passed":4,"ratio":1},{"days":30,"observed":4,"passed":4,"ratio":1},{"days":90,"observed":4,"passed":4,"ratio":1}],"history_90d":[{"observed_at":"2026-10-01T09:29:06.018Z","state":"pass","failed_checks":[],"run_id":"daily-2026-10-01","state_changed":false},{"observed_at":"2026-09-30T08:57:24.392Z","state":"pass","failed_checks":[],"run_id":"daily-2026-09-30","state_changed":false},{"observed_at":"2026-09-29T21:02:23.398Z","state":"pass","failed_checks":[],"run_id":"daily-2026-09-29","state_changed":false},{"observed_at":"2026-09-28T16:49:01.679Z","state":"pass","failed_checks":[],"run_id":"new-after-daily-2026-09-28","state_changed":true}]},"seller":{"wallet":"0x836Be278f1739fB4308091cD1852F7971Bc19Ee2","page":"https://tollindex.com/seller/0x836Be278f1739fB4308091cD1852F7971Bc19Ee2","endpoints":844,"hosts":1},"reports":0,"registry_record":{"cdp":[{"tags":["epiphany","pe","cancer","vte","calculator"],"type":"http","accepts":[{"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","extra":{"name":"USD Coin","version":"2","paymentFlow":"upfront","resourceUrl":"https://api.magentlab.com/api/calc/epiphany","assetTransferMethod":"eip3009"},"payTo":"0x836Be278f1739fB4308091cD1852F7971Bc19Ee2","amount":"5000","scheme":"exact","network":"eip155:8453","maxTimeoutSeconds":600}],"quality":{"lastCalledAt":"2026-09-28T14:26:52.613Z","l30DaysTotalCalls":1,"l30DaysUniquePayers":1},"resource":"https://api.magentlab.com/api/calc/epiphany","extensions":{"bazaar":{"info":{"input":{"body":{"items":[{"ecog_ps_ge_2":false,"hestia_like_any":false,"oxygen_sat_lt_90":false,"tumour_uncontrolled":false,"pe_specific_symptoms":false,"primary_tumour_resected":true},{"ecog_ps_ge_2":false,"hestia_like_any":false,"oxygen_sat_lt_90":false,"tumour_uncontrolled":false,"pe_specific_symptoms":false,"primary_tumour_resected":true}]},"type":"http","method":"POST"},"output":{"type":"json","example":{"path":"/api/calc/epiphany","count":2,"items":[{"leaf":"low_controlled","formula":"epiphany","citation":{"id":"carmona-bayonas-2017","doi":"10.1038/bjc.2017.48","pmid":"28267709","title":"Predicting serious complications in patients with cancer and pulmonary embolism using decision tree modelling: the EPIPHANY Index","source":"Br J Cancer. 2017;116:994-1001","authors":"Carmona-Bayonas A, Jiménez-Fonseca P, Font C, Fenoy F, Otero R, Beato C, Plasencia JM, Biosca M, Sánchez M, Benegas M, Calvo-Temprano D, Varona D, Faez L, de la Haba I, Antonio M, Madridano O, Solis MP, Ramchandani A, Castañón E, Marchena PJ, Martín M, Ayala de la Peña F, Vicente V; Asociación de Investigación de la Enfermedad Tromboembólica de la Región de Murcia"},"criteria":[{"met":false,"factor":"hestia_like_any"},{"met":false,"factor":"ecog_ps_ge_2"},{"met":false,"factor":"oxygen_sat_lt_90"},{"met":false,"factor":"pe_specific_symptoms"},{"met":false,"factor":"tumour_uncontrolled"},{"met":true,"factor":"primary_tumour_resected"}],"disclaimer":"Not a medical device. Deterministic published-formula or published-code output for autonomous agents. A licensed clinician remains responsible for patient care and billing submissions.","risk_class":"low","ecog_ps_ge_2":false,"hestia_like_any":false,"oxygen_sat_lt_90":false,"formula_expression":"root: hestia-like CDR any vs none (Carmona-Bayonas 2017 Figure 2). CDR any: ECOG-PS >=2 then SaO2 <90 vs >=90 (both high), else PE-specific symptoms yes (high) vs no (intermediate). CDR none: tumour progression/unknown/not evaluated vs others (CR/PR/SD/NED); if uncontrolled then primary tumour resection yes (low) vs no (intermediate); if others then low. Classes low/intermediate/high with 15-day serious complications 1.6/9.4/30.6% and 15-day mortality 0.3/6.1/17.1%","tumour_uncontrolled":false,"pe_specific_symptoms":false,"mortality_15d_percent":0.3,"primary_tumour_resected":true,"serious_complication_15d_percent":1.6},{"leaf":"low_controlled","formula":"epiphany","citation":{"id":"carmona-bayonas-2017","doi":"10.1038/bjc.2017.48","pmid":"28267709","title":"Predicting serious complications in patients with cancer and pulmonary embolism using decision tree modelling: the EPIPHANY Index","source":"Br J Cancer. 2017;116:994-1001","authors":"Carmona-Bayonas A, Jiménez-Fonseca P, Font C, Fenoy F, Otero R, Beato C, Plasencia JM, Biosca M, Sánchez M, Benegas M, Calvo-Temprano D, Varona D, Faez L, de la Haba I, Antonio M, Madridano O, Solis MP, Ramchandani A, Castañón E, Marchena PJ, Martín M, Ayala de la Peña F, Vicente V; Asociación de Investigación de la Enfermedad Tromboembólica de la Región de Murcia"},"criteria":[{"met":false,"factor":"hestia_like_any"},{"met":false,"factor":"ecog_ps_ge_2"},{"met":false,"factor":"oxygen_sat_lt_90"},{"met":false,"factor":"pe_specific_symptoms"},{"met":false,"factor":"tumour_uncontrolled"},{"met":true,"factor":"primary_tumour_resected"}],"disclaimer":"Not a medical device. Deterministic published-formula or published-code output for autonomous agents. A licensed clinician remains responsible for patient care and billing submissions.","risk_class":"low","ecog_ps_ge_2":false,"hestia_like_any":false,"oxygen_sat_lt_90":false,"formula_expression":"root: hestia-like CDR any vs none (Carmona-Bayonas 2017 Figure 2). CDR any: ECOG-PS >=2 then SaO2 <90 vs >=90 (both high), else PE-specific symptoms yes (high) vs no (intermediate). CDR none: tumour progression/unknown/not evaluated vs others (CR/PR/SD/NED); if uncontrolled then primary tumour resection yes (low) vs no (intermediate); if others then low. Classes low/intermediate/high with 15-day serious complications 1.6/9.4/30.6% and 15-day mortality 0.3/6.1/17.1%","tumour_uncontrolled":false,"pe_specific_symptoms":false,"mortality_15d_percent":0.3,"primary_tumour_resected":true,"serious_complication_15d_percent":1.6}]}},"iconUrl":"https://api.magentlab.com/favicon.ico"},"schema":{"type":"object","$schema":"https://json-schema.org/draft/2020-12/schema","required":["input"],"properties":{"input":{"type":"object","required":["type","method"],"properties":{"body":{"type":"object","required":["items"],"properties":{"items":{"type":"array","items":{"type":"object","required":["hestia_like_any","ecog_ps_ge_2","oxygen_sat_lt_90","pe_specific_symptoms","tumour_uncontrolled","primary_tumour_resected"],"properties":{"ecog_ps_ge_2":{"type":"boolean","description":"ECOG-PS >=2 as assigned by the caller (Carmona-Bayonas 2017: <2 vs >=2). true or false. Used on the Hestia-like-any branch. magent does not assign performance status."},"hestia_like_any":{"type":"boolean","description":"true if any Carmona-Bayonas 2017 Hestia-like clinical decision rule item is present: SBP <100 mm Hg, arterial oxygen saturation <90%, respiratory rate >=30 breaths/min, pulse >=110 beats/min, sudden or progressive dyspnoea, or clinically relevant haemorrhage / high bleeding risk / platelets <50 000 mm^-3 (Figure 2). false if none. Caller-assigned; magent does not measure vitals or score the 11-item Zondag Hestia checklist."},"oxygen_sat_lt_90":{"type":"boolean","description":"Arterial oxygen saturation <90% as assigned by the caller (Figure 2: <90 vs >=90%). true or false. Used when Hestia-like any is present and ECOG-PS >=2; both sat leaves are high class. Distinct from the same cutoff inside the Hestia-like CDR. magent does not measure saturation."},"tumour_uncontrolled":{"type":"boolean","description":"true if tumour response is progression, unknown, or not evaluated; false for others (complete or partial response, stable disease, or no evidence of disease) per Carmona-Bayonas 2017 Table 1 / Figure 2. Used on the Hestia-like-none branch. magent does not apply RECIST."},"pe_specific_symptoms":{"type":"boolean","description":"PE-specific symptoms present as assigned by the caller (Carmona-Bayonas 2017 Figure 2). true or false. Used when Hestia-like any is present and ECOG-PS <2. Distinct from incidental vs symptomatic diagnosis and from the dyspnoea CDR item. magent does not take a history."},"primary_tumour_resected":{"type":"boolean","description":"Prior surgical resection of the primary tumour as assigned by the caller. true or false. Used when Hestia-like none and tumour_uncontrolled are both true. magent does not read an operative note."}}},"maxItems":25,"minItems":1}},"additionalProperties":false},"type":{"type":"string","const":"http"},"method":{"type":"string","const":"POST"},"headers":{"type":"object","additionalProperties":{"type":"string"}}},"additionalProperties":false},"output":{"type":"object","required":["type"],"properties":{"type":{"type":"string"},"example":{"type":"object"}}}}}}},"description":"Carmona-Bayonas 2017 EPIPHANY CHAID tree for cancer-associated PE. Hestia-like CDR any vs none, then ECOG-PS, SaO2, PE symptoms, tumour response, and primary resection as in Figure 2. Returns low, intermediate, or high with 15-day complication rates 1.6/9.4/30.6% and mortality 0.3/6.1/17.1%. Caller assigns the six covariates. Not a diagnosis or anticoagulation order. magent does not examine the patient.","lastUpdated":"2026-09-28T14:26:52.747Z","serviceName":"magent","x402Version":2}]}}